LT3001 for Adults Having an Acute Ischemic Stroke

Trial details

Who runs it

Shanghai Pharmaceuticals Holding Co., Ltd

Trial code

NCT07754825

Record updated

19 October 2026

Original description

This phase II clinical study is designed to evaluate the efficacy and safety of LT3001 in the treatment of acute ischemic strokeRead full original descriptionShow less

A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of LT3001 in Participants With Acute Ischemic Stroke (AIS)

This phase II clinical study is designed to evaluate the efficacy and safety of LT3001 in the treatment of acute ischemic stroke

Inclusion: Clinical diagnosis of acute ischemic stroke that causes evaluable neurological impairment; 6 points ≤ NIHSS score ≤ 25 points at randomization; Participants who are able to receive the investigational drug within 24 hours after the onset of stroke; Female Participants of childbearing potential or male Participants whose sexual partner are women of childbearing potential have no pregnancy plan and voluntarily take effective contraceptive measures during the study period and for 3 months after the last dose; All participants sign the informed consent form by themselves or their guardians after receiving complete study information.

Exclusion: Participants have received or plan to receive endovascular treatment and/or intravenous thrombolytic therapyduring this onset period; Participants who have used or are using protocol-prohibited medications after the onset; Participants who are unable to cooperate due to epileptic seizure at the onset of stroke or other concomitant mental disorders or are unwilling to cooperate; Participants previously diagnosed with concurrent malignant tumors who are currently undergoing anti-tumor treatment or have an expected survival of less than 3 months；; Systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 100 mmHg after active antihypertensive therapy; Participants who underwent any major surgery before screening; Participants who have participated in another investigational study and used investigational product before screening; Participants with pre-stroke disability; Imaging evidence of intracranial hemorrhagic diseases, intraparenchymal brain tumor, arteriovenous malformation, aortic arch dissection, other central nervous system lesions that may increase the risk of hemorrhage, or arterial aneurysm requiring treatment; Acute hemorrhage tendency; Active visceral hemorrhage; Participants with a history of serious hypersensitivity; Participants who experienced AIS, ICH, acute myocardial infarction or serious head trauma before screening; Participants with a history of active digestive ulcer before screening; Participants who experienced hemorrhagic disease before screening; Presence of active hepatitis, cirrhosis, or severe renal insufficiency; Other conditions unsuitable for participation in this study determined by the Investigator; Blood glucose level < 50 mg/dL or > 400 mg/dL; Presence of disturbances of consciousness at screening and NIHSS 1a ≥ 2 points; Neurological signs have improved rapidly and spontaneously at screening; Massive infarction on imaging; Lactating or pregnant Participants, or women of childbearing potential with positive pregnancy test results; International normalized ratio > 1.7 or prothrombin time > 15 s; Participants who underwent arterial puncture at the site not easy for hemostasis by compression before screening.

ClinicalTrials.gov NCT07754825